Molecular correlates differentiate the response to atezolizumab (Atezo) + bevacizumab (Bev) vs. Sunitinib (Sun): results of a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

Maintenance treatment with ixazomib after autologous stem cell transplantation significantly prolongs the progression-free survival of newly diagnosed multiple myeloma patients: Phase 3 study TOURMALINE-MM3

Patients in the CheckMate 214 study who discontinued first-line treatment for advanced renal cell carcinoma with nivolumab + ipilimumab or sunitinib due to treatment-related adverse events

Patient-reported results (PROs) with Durvalumab after PD-L1 expression in unresectable stage III NSCLC (PACIFIC)

Genomic Characterization and Molecular Risk Markers in Patients with DIPSS Low Risk and Intermediate Risk-1 Primary Myelofibrosis (PMF)

Elotuzumab in combination with pomalidomide and dexamethasone in relapsed / refractory multiple myeloma (RRMM): Follow-up efficacy data in the randomized phase 2 ELOQUENT-3 study

Influence of subsequent immunotherapy after discontinuation of study therapy on the overall survival of patients with non-operable, stage III NSCLC from the PACIFIC study

Follow-up study with patients with CML in all stages treated with ponatinib (Iclusig (R)) at any dose

Prevalence of "Programmed Death Ligand-1" (PD-L1) by demographic, disease and specimen-specific features in inoperable stage III NSCLC

HER2 positive gastric carcinoma: Mean HER2 expression is associated with high variation in HER2 test results between local and central pathology and poorer survival

Prognostic significance of general condition and comorbidity scores for the efficacy and treatment-associated toxicity of lenalidomide consolidation and maintenance therapy in patients with multiple myeloma after high-dose therapy in the prospective randomized LenaMain study

Bosutinib for previously treated CML patients in chronic phase: results of the BYOND study

Dasatinib (DAS) versus imatinib (IMA) in the treatment of patients with chronic myeloid leukemia in the chronic phase (CML-CP) who failed to achieve optimal response during 3 months of treatment with IMA: 2-year update the DASCERN study

Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients treated with immuno-checkpoint inhibitors: Current data from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)

Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the Phase III FLAURA study